These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34265280)

  • 1. A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Lu X; Yan G; Dawood M; Klauck SM; Sugimoto Y; Klinger A; Fleischer E; Shan L; Efferth T
    Biochem Pharmacol; 2021 Dec; 194():114677. PubMed ID: 34265280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K
    Dawood M; Hegazy MF; Elbadawi M; Fleischer E; Klinger A; Bringmann G; Kuntner C; Shan L; Efferth T
    Biochem Pharmacol; 2020 Oct; 180():114176. PubMed ID: 32721508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
    Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
    Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
    Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
    Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
    Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
    Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.
    Abdulwahab HG; Mansour RE; Farghaly TA; El-Sehrawi HM
    Bioorg Chem; 2024 May; 146():107284. PubMed ID: 38493640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
    Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
    Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
    Cao B; Li J; Zhu J; Shen M; Han K; Zhang Z; Yu Y; Wang Y; Wu D; Chen S; Sun A; Tang X; Zhao Y; Qiao C; Hou T; Mao X
    J Biol Chem; 2013 Nov; 288(47):34181-34189. PubMed ID: 24114842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
    Xie R; Li Y; Tang P; Yuan Q
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
    Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
    J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.
    Bär SI; Dittmer A; Nitzsche B; Ter-Avetisyan G; Fähling M; Klefenz A; Kaps L; Biersack B; Schobert R; Höpfner M
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35485292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.